Pfizer tops forecasts as total Covid vaccine sales soar

Pfizer earned a total of £5.97 billion in the third quarter (Mark Lennihan/AP)

US pharmaceutical firm Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the Covid-19 vaccine Comirnaty, slipped in America.

Soaring international sales of the vaccine helped push total Comirnaty revenue close to 13 billion US dollars (£9.5 billion) in the quarter, and the company said it now expected to book about 36 billion US dollars (£26 billion) in sales from the vaccine this year.